Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

被引:0
|
作者
Gavin M Bendle
Carsten Linnemann
Anna I Hooijkaas
Laura Bies
Moniek A de Witte
Annelies Jorritsma
Andrew D M Kaiser
Nadine Pouw
Reno Debets
Elisa Kieback
Wolfgang Uckert
Ji-Ying Song
John B A G Haanen
Ton N M Schumacher
机构
[1] The Netherlands Cancer Institute,Division of Immunology
[2] Laboratory of Experimental Tumor Immunology,Department of Medical Oncology
[3] Erasmus MC-Daniel den Hoed Cancer Center,Division of Experimental Animal Pathology
[4] Max Delbrück Center for Molecular Medicine,Division of Medical Oncology
[5] The Netherlands Cancer Institute,undefined
[6] The Netherlands Cancer Institute,undefined
来源
Nature Medicine | 2010年 / 16卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
T cell receptor (TCR) gene therapy is a promising immunotherapy for cancer and infectious disease. But introducing exogenous TCR α and β chains into T cells may have unintended consequences. In this issue, Bendle et al. show that the transfer of TCR-transduced T cells into mice triggered a lethal pathology that resembles graft-versus-host disease and is caused by the pairing of endogenous and exogenous TCR chains resulting in autoreactive T cells (pages 520–521).
引用
收藏
页码:565 / 570
页数:5
相关论文
共 50 条
  • [21] INVOLVEMENT OF MACROPHAGES IN LETHAL FORMS OF GRAFT-VERSUS-HOST DISEASE
    FACON, T
    JANIN, A
    NOEL, MP
    JOUET, JP
    LANCET, 1995, 345 (8946): : 392 - 392
  • [22] A protective gene for graft-versus-host disease
    Cooke, KR
    Ferrara, JLM
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23): : 2183 - 2184
  • [23] TCR transgenic regulatory T cells prevent lethal graft-versus-host disease
    Sorge, Y
    Ostermann, P
    Bayer, B
    Klempnauer, J
    Hoffmann, MW
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 90 - 91
  • [24] Efficacy of azithromycin in preventing lethal graft-versus-host disease
    Iwamoto, S.
    Azuma, E.
    Kumamoto, T.
    Hirayama, M.
    Yoshida, T.
    Ito, M.
    Amano, K.
    Ido, M.
    Komada, Y.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 171 (03): : 338 - 345
  • [25] Therapy of chronic graft-versus-host disease
    Arora, Mukta
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (02) : 271 - 279
  • [26] Ruxolitinib for Therapy of Graft-versus-Host Disease
    Neumann, Thomas
    Schneidewind, Laila
    Weigel, Martin
    Plis, Andrzej
    Vaizian, Rem
    Schmidt, Christian A.
    Krueger, William
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [27] Ruxolitinib for therapy of graft-versus-host disease
    Plis, A.
    Neumann, T.
    Schneidewind, L.
    Weigel, M.
    Vaizian, R.
    Schmidt, C.
    Krueger, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 205 - 205
  • [28] Natural killer cell receptor gene expression in cutaneous graft-versus-host disease.
    Miura, Y
    Thoburn, CJ
    Bright, EC
    Phelps, ML
    Vogelsang, GB
    Hess, AD
    BLOOD, 2003, 102 (11) : 702A - 703A
  • [29] IN-VIVO T-CELL RECEPTOR LIGATION FACILITATES ALLOENGRAFTMENT AND PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE (GVHD) IN MICE
    BLAZAR, BR
    TAYLOR, PA
    VALLERA, DA
    BONE MARROW TRANSPLANTATION, 1993, 12 : S38 - S40
  • [30] Human-based T cell-skin models for graft-versus-host disease
    Geiger, F.
    Tumbev, Y.
    Groeber-Becker, F. K.
    Berberich-Siebelt, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S276 - S276